|
Commitments and Contingencies - Additional Information (Detail) (USD $)
|
3 Months Ended |
|
Mar. 31, 2015
|
| UFRF License Agreements [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
5.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Company's obligation to pay from all revenue received from sublicenses |
22.00%ogen_RoyaltyPaymentPercentageSublicenses
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| One-time commercialization fee monthly amount for calculation |
$ 5,000ogen_MonthlyCalculationOfCommercializationFee
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Post-commercialization minimum royalty payments |
50,000ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount |
2,000,000ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| One-time additional payment to UFRF as a percentage of total royalties due to UFRF |
10.00%ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Minimum annual maintenance payment per license agreement |
10,000ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Aggregate minimum annual maintenance payment |
20,000ogen_AggregateMinimumAnnualMaintenancePayment
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Quarterly maintenance payment to UFRF under installment plan |
5,000ogen_MinimumQuarterlyMaintenancePayment
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Texas A and M University License [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
5.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Post-commercialization minimum royalty payments |
100,000ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Initial payment to Texas A&M |
5,000ogen_InitialPaymentForLicensingAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Minimum consideration for the continuation of the license agreement |
15,000ogen_MinimumConsiderationForContinuationOfLicenseAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Annual maintenance payment under licensing agreement with Texas A&M |
100,000ogen_AnnualMaintenancePaymentUnderLicensingAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Maximum period to cure the breach |
60 days
|
| Texas A and M University License [Member] | Phase I Clinical Trial [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Date of milestone achievement under licensing agreement with Texas A&M |
Jun. 01, 2015
|
| Milestone payment under licensing agreement |
50,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseOneClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Texas A and M University License [Member] | Phase II Clinical Trial [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Date of milestone achievement under licensing agreement with Texas A&M |
Jun. 01, 2019
|
| Milestone payment under licensing agreement |
100,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseTwoClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Texas A and M University License [Member] | Phase III Clinical Trial [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Date of milestone achievement under licensing agreement with Texas A&M |
Jun. 01, 2022
|
| Milestone payment under licensing agreement |
150,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseThreeClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Texas A and M University License [Member] | Sale Of Licensed Technology [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Date of milestone achievement under licensing agreement with Texas A&M |
Jun. 01, 2025
|
| Milestone payment under licensing agreement |
400,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_SaleOfLicensedTechnologyMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Texas A and M University License [Member] | Minimum [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
2.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasAandMUniversityLicenseMember
|
| Lantibiotic ECC [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
25.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Company's obligation to pay from all revenue received from sublicenses |
50.00%ogen_RoyaltyPaymentPercentageSublicenses
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Number of shares issued |
4,392,425us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Maximum percentage of primary investment securities to investment of shares issued |
10.00%ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Number of milestones achieved |
0ogen_NumberOfMilestonesAchieved
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Termination notice period |
90 days
|
| Lantibiotic ECC [Member] | Investigational New Drug Application [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
1.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_InvestigationalNewDrugApplicationMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Lantibiotic ECC [Member] | Clinical Study Phase 2 [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
1.50%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_ClinicalStudyPhaseTwoMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Lantibiotic ECC [Member] | Clinical Study Phase 3 [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
2.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_ClinicalStudyPhaseThreeMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Lantibiotic ECC [Member] | Filing of First Investigational New Drug Application [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
2.50%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_FilingOfFirstInvestigationalNewDrugApplicationMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| Lantibiotic ECC [Member] | First Regulatory Approval of Oragenics Product [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
3.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_FirstRegulatoryApprovalOfOragenicsProductMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticExclusiveChannelCollaborationMember
|
| LBPs ECC [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
10.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
|
| Maximum period to cure the breach |
60 days
|
| Number of milestones achieved |
0ogen_NumberOfMilestonesAchieved
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
|
| LBPs ECC [Member] | Phase II Clinical Trial [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Milestone payment under licensing agreement |
2,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseTwoClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
|
| Milestone measurement period |
30 days
|
| LBPs ECC [Member] | Phase III Clinical Trial [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Milestone payment under licensing agreement |
5,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseThreeClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
|
| Milestone measurement period |
30 days
|
| LBPs ECC [Member] | Sale Of Licensed Technology [Member] |
|
| Commitment And Contingencies [Line Items] |
|
| Milestone payment under licensing agreement |
$ 10,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_SaleOfLicensedTechnologyMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LiveBiotherapeuticProductsExclusiveChannelCollaborationMember
|
| Milestone measurement period |
30 days
|